20 completed, 7 recruiting, 3 not yet recruiting, 2 terminated. 35 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 35 | Completed 20, Recruiting 7, Not yet recruiting 3, Terminated 2, Unknown 2, Withdrawn 1 |
Follow Crystal Arthropathies: new trials by email Literature Review of Crystal Arthropathies trials Research Report on Crystal Arthropathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mazdutide for Weight Management and Gout in Adults With Obesity Mazdutide - Gout, Obesity (BMI>30) | Phase 4 | Not yet recruiting | Hongwei Jiang | 30 | 2026-09-15 | 2026-09-17 |
| The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time Dotinurad, colchicine, etoricoxib - Gout | Phase 4 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 142 | 2026-07-30 | 2026-06-22 |
| SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial Empagliflozin 10 mg, Placebo - Gout and Hyperuricemia | Phase 4 | Recruiting | Massachusetts General Hospital | 60 | 2026-07-01 | 2026-08-05 |
| HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness HLA-B*58:01 Genotyping, Allopurinol Tablet, Febuxostat - Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis | Phase 4 | Not yet recruiting | Haiphong University of Medicine and Pharmacy | 228 | 2026-01-20 | 2026-01-27 |
| Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares Purified Cortophin Gel, 40 U, Purified Cortophin Gel 80 U - Gout Arthritis, Gout Flare | Phase 4 | Recruiting | Massachusetts General Hospital | 150 | 2025-12-20 | 2026-01-20 |
| the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More Febuxostat - Gout, Uric Acid | Phase 4 | Recruiting | Seoul National University Hospital | 59 | 2025-09-10 | 2026-04-29 |
| Effect of Dotinurad in Hyperuricemia With Hypertension Dotinurad, Febuxostat - Hyperuricemia or Gout, Hypertension | Phase 4 | Recruiting | Saga University | 360 | 2025-03-28 | 2025-12-15 |
| Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets Sodium Bicarbonate Oral Capsule, Potassium Citrate Tablets, uric-acid-lowering drug - Hyperuricemia or Gout, Nephrolithiasis | Phase 4 | Recruiting | Huashan Hospital | 312 | 2024-04-10 | 2025-05-13 |
| A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout Pegloticase, Methotrexate - Gout | Phase 4 | Completed | Amgen | 306 | 2024-03-18 | 2026-09-17 |
| Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout Allopurinol, Naproxen 250 MG, Colchicine 0.6 mg - Gout | Phase 4 | Recruiting | Massachusetts General Hospital | 650 | 2024-02-22 | 2025-09-25 |
| Effect of Atelocollagen Injection in Patients With Calcific Tendinitis Atelocollagen - Calcific Tendinitis of Shoulder, Atelocollagen | Phase 4 | Unknown | Hyungsuk Kim | 46 | 2023-12-06 | 2024-04-12 |
| Bioinductive Patch for Full-Thickness Rotator Cuff Tears arthroscopic rotator cuff repair, Bioinductive implant, Ultrasound Imaging - Rotator Cuff Tears, Rotator Cuff Tear Arthropathy | Phase 4 | Recruiting | Henry Ford Health System | 78 | 2022-08-16 | 2026-02-27 |
| Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy Pegloticase, Methotrexate (MTX) - Uncontrolled Gout | Phase 4 | Completed | Amgen | 11 | 2021-03-08 | 2024-06-27 |
| A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL) Pegloticase, Methotrexate (MTX) - Uncontrolled Gout, Chronic Gout | Phase 4 | Completed | Amgen | 54 | 2021-01-26 | 2026-05-19 |
| Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate Pegloticase with MTX - Chronic Uncontrolled Gout, Gout | Phase 4 | Completed | Amgen | 191 | 2020-10-02 | 2025-10-20 |
| Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout Pegloticase, methotrexate, placebo - Gout | Phase 4 | Completed | Amgen | 152 | 2019-06-13 | 2024-06-26 |
| Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout Pegloticase, Methotrexate (MTX), Standard Gout Flare Prophylaxis - Gout | Phase 4 | Completed | Amgen | 14 | 2018-09-26 | 2024-06-26 |
| The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF) Febuxostat 80 MG Oral Tablet or Allopurinol 300 MG Oral Tablet - Gout, CKD Stage 1-4 | Phase 4 | Unknown | Medical Practice Prof D. Ivanov | 2 | 2017-10-30 | 2022-08-24 |
| A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment Lesinurad, XOI, Placebo - Gout, Chronic Kidney Disease (CKD) | Phase 4 | Terminated | Ironwood Pharmaceuticals, Inc. | 242 | 2017-07-19 | 2021-11-04 |
| CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat allopurinol capsule, 100-800 mg by mouth once daily, febuxostat tablet 40-120 mg by mouth once daily, Placebo, vehicle control (febuxostat-shaped) - Gout, Chronic Kidney Diseases | Phase 4 | Completed | VA Office of Research and Development | 950 | 2017-03-06 | 2024-03-29 |
Showing 20 of 35. Sign in to see all of them.
Gout (31) · Hyperuricemia (8) · Rotator Cuff Tear Arthropathy (4) · Arthritis, Gouty (2) · Hypertension (2) · Osteoarthritis (2) · Renal Insufficiency, Chronic (2) · Arthritis (1) · Cardiovascular Diseases (1) · Chondrocalcinosis (1) · Diabetes Mellitus (1) · Inflammation (1) · Metabolic Syndrome (1) · Nephrolithiasis (1) · Obesity (1)
Joint Diseases (35) · Musculoskeletal Diseases (35) · Arthritis (34) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (31) · Genetic Diseases, Inborn (31) · Metabolic Diseases (31) · Metabolism, Inborn Errors (31) · Nutritional and Metabolic Diseases (31) · Purine-Pyrimidine Metabolism, Inborn Errors (31) · Rheumatic Diseases (31) · Pathological Conditions, Signs and Symptoms (11) · Pathologic Processes (10) · Chondrocalcinosis (4) · Female Urogenital Diseases (4)
Allopurinol (11) · Febuxostat (10) · Colchicine (7) · Methotrexate (6) · Pegloticase (6) · Naproxen (3) · Folic Acid (2) · dotinurad (2) · Acetaminophen (1) · Adrenal Cortex Hormones (1) · Canagliflozin (1) · Etoricoxib (1) · Food (1) · Magnetic Resonance Spectroscopy (1) · Methylprednisolone (1)
Amgen (6) · Massachusetts General Hospital (3) · 59th Medical Wing (1) · Ardea Biosciences, Inc. (1) · CherryPharm (1) · DePuy International (1) · First Affiliated Hospital of Wenzhou Medical University (1) · Haiphong University of Medicine and Pharmacy (1) · Henry Ford Health System (1) · Hongwei Jiang (1) · Huashan Hospital (1) · Hyungsuk Kim (1) · Ironwood Pharmaceuticals, Inc. (1) · Keele University (1) · Maisonneuve-Rosemont Hospital (1)
United States (20) · Canada (2) · Germany (2) · Italy (2) · Poland (2) · South Korea (2) · Australia (1) · Belgium (1) · China (1) · Czechia (1) · France (1) · Hungary (1) · Japan (1) · Netherlands (1) · New Zealand (1)
Hyon K Choi, MD, DrPH (2) · Claudio Borghi, Prof (1) · Daniel O'Connor, UCSD (1) · Ed Roddy (1) · Ernesto J Rodriguez, MD (1) · H. R Schumacher, M.D. (1) · Hongwei Jiang, MD (1) · Hyon K Choi, MD, PhD (1) · James R O'Dell (1) · Jason T. Davis, M.D. (1) · Jay B Higgs, MD (1) · John D Carter, MD (1)
PMID 23098865, PMID 26190562, PMID 30975645, PMID 31666237, PMID 32877573, PMID 32934137, PMID 33719606, PMID 34438469, PMID 35293984, PMID 35434725, PMID 35835008, PMID 36008814, PMID 36099211, PMID 36575505, PMID 36945579, PMID 36993363, PMID 37842953, PMID 38260556, PMID 38447697, PMID 38766125, PMID 39426967, PMID 39678124, PMID 42775939
2014 (1), R21DK105401 (1), R61AR084188 (1), U01AR080985 (1)